Promega builds plant to produce regulated products

Published: 29-Aug-2011
Manufacturing Analysis

Including sample preparation systems and reagents

Promega Corporation, based in Madison, Wisconsin, US, has held a ground-breaking ceremony for a new cGMP facility to support business growth and customers who need FDA-regulated molecular biology products. These include sample preparation systems and reagents, which are part of diagnostic and medical tests sold by human diagnostic test providers.

The 260,000ft2 (24,150m2) facility will require an additional 100 people in the next five years. Most of the building will be dedicated to fixed and flexible manufacturing areas. It will also house a customer experience centre for training, laboratory demonstrations and conferences.

‘This building is our next step in expanding our product supply capabilities worldwide,’ said ceo Bill Linton.

Plans include a number of sustainable practices, including geothermal heating and cooling, dark sky compliant lighting, prairie restoration, bio-retention ponds for storm water run off among other sustainable features and construction practices.

Promega Corporation provides solutions and technical support to the life sciences industry. Its 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification.

See more

You may also like

Manufacturing

Promega opens new Shanghai facility

Read more
Provides additional r&d and cGMP manufacturing capabilities

Trending Articles

  1. MOBILion Systems demonstrates a new paradigm in mass-spectrometry based proteomics MOBILion Systems has achieved proof-of-concept demonstrating that its proprietary PAMAF mode of high-resolution ion mobility (HRIM) overcomes hardware limitations in existing LC-MS/MS workflows
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    The two sides of sustainable packaging in pharmaceuticals Rewriting pharma’s packaging footprint in more ways than one
  3. Inside the shift toward greener, faster, Smarter drug manufacturing Dave Henderson, Ph.D, MBA, Head of R&D Labs at Asymchem explores the pharmaceutical manufacturing landscape and the challenges CDMOs must address to remain competitive in this shifting market
  4. API manufacturing process development steps: from filtration to finishing Developing an active pharmaceutical ingredient (API) is a lengthy process. It begins in a lab and ends with a finely tuned, highly regulated product ready for formulation and patient delivery. Between these two points lie a series of critical process development steps, each with its own challenges, regulatory demands, and opportunities for optimisation. That’s where API process development makes all the difference
  5. SÜDPACK Medica showcases recyclable blister and medical packaging innovations at PharmaPack 2026 From recyclable PP blisters to cleanroom-manufactured pouch solutions, SÜDPACK Medica highlights sustainability and performance in pharma packaging

Upcoming event

High Shear = Mixing Success

19 February 2026 | Virtual See all

You may also like

Manufacturing

Promega opens new Shanghai facility

Provides additional r&d and cGMP manufacturing capabilities
Manufacturing

Vetter Pharma to build new manufacturing site in Germany as part of €1.5bn global expansion plan

The company has submitted a building permit application for a new commercial manufacturing facility in Saarland, Germany, with construction set to begin in Q2 2026 and operations planned for 2031
Manufacturing

Torque of the town - Powerful overhead stirrers from Caframo Lab Solutions

In the UK, Labtex proudly supply a powerful range of overhead stirrers and quality accessories from trusted partners at Caframo Lab Solutions
Manufacturing

Key factors in engineering a perfect vacuum drying cycle – from agitator stroke to cake height

Pharmaceuticals demand exceptional control at every stage of production to maintain product integrity and maximise recovery. Drying is particularly critical, as it determines how much material is recovered and whether key attributes like stability, crystal form, and residual solvent content remain within specification
Analysis

UK biotech ends 2025 resilient as investor confidence returns, BIA reports

UK biotech finished 2025 with renewed momentum despite a challenging investment climate, according to the BioIndustry Association, with a strong Q4 rebound and growing policy support boosting confidence as the sector heads into 2026
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

The two sides of sustainable packaging in pharmaceuticals

Rewriting pharma’s packaging footprint in more ways than one
Manufacturing

LabIndex - Sourcing solutions powered by a network of world-class suppliers

Labtex states: "Using our experience and negotiating power, we can speedily source and procure virtually any type of laboratory equipment or consumables at competitive prices."
Subscribe now